| Name: | Emtricitabine R-sulfoxide |
| Catalogue No. | VE006636 |
| CAS No. | N/A |
| Molecular Formula | C8H10FN3O4S |
| Molecular Weight | 263.25 |
| Status | In-stock |
| IUPAC Name | 5-fluoro-1-[(2R,3R,5S)-2-(hydroxymethyl)-3-oxo-1,3-oxathiolan-5-yl]cytosine |
| Description | Emtricitabine R-sulfoxide or 5-fluoro-1-[(2R,3R,5S)-2-(hydroxymethyl)-3-oxo-1,3-oxathiolan-5-yl]cytosine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for the use in combination therapy. |
| References | "Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://do |
